{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-046970","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.966920+00:00","generated_at":"2026-06-03T22:54:38.345742+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.","bullets":["OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.","Builds on OviTex portfolio with >45,000 implantations and 8 years clinical experience.","Study on 259 patients using ReBAR technique showed low 1.2% recurrence rate at 1.5-year follow-up.","Designed for laparoscopic and robotic-assisted repair; aims to address shortcomings of permanent synthetic mesh."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-046970","json":"https://secwatch.observer/filing/0001104659-24-046970.json","markdown":"https://secwatch.observer/filing/0001104659-24-046970.md","text":"https://secwatch.observer/filing/0001104659-24-046970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/0001104659-24-046970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/tm2411582d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:54:38.345742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}